// Index Comparison

ACCE Cybersecurity vs ACCE Biotech Catalysts

Head-to-head: performance, risk profile, and constituent overlap between two ACCE indices.

Zero-trust adoption, cloud security, and identity protection. The cybersecurity spend cycle is structural, not cyclical.

ACCE Biotech Catalysts →

Binary catalyst pipeline — FDA approvals, late-stage trial readouts, and M&A targets. High conviction names with visible catalysts.

Performance windows

Period	ACCE Cybersecurity	ACCE Biotech Catalysts	Spread
1M	+13.0%	-1.3%	+14.3%
3M	-1.9%	-11.5%	+9.6%
YTD	-3.1%	-7.6%	+4.5%
1Y	-3.1%	-7.6%	+4.5%
3Y	-3.1%	-7.6%	+4.5%
5Y	-3.1%	-7.6%	+4.5%
Inception	-3.1%	-7.6%	+4.5%

ACCE Cybersecurity — risk

Volatility 30d+46.2%

Volatility 90d+42.2%

Sharpe 90d-0.13

Max drawdown-24.3%

Beta vs CIBR0.94

ACCE Biotech Catalysts — risk

Volatility 30d+21.6%

Volatility 90d+25.2%

Sharpe 90d-1.05

Max drawdown-13.4%

Beta vs SPY0.91

Constituent overlap

0 stocks held by both indices (out of 5 and 6)

Top sectors — ACCE Cybersecurity

Technology100.0%

Top sectors — ACCE Biotech Catalysts

Healthcare100.0%

ACCE Verdict

ACCE Cybersecurity has outperformed ACCE Biotech Catalysts since inception, losing 3.14% versus biotech's 7.6% decline, though both trail the benchmark's 4.74% gain.

The risk profiles tell different stories: Cybersecurity runs much hotter with 42.2% volatility and a brutal 24.3% maximum drawdown, while Biotech Catalysts shows more contained 25.2% volatility and 13.4% drawdown despite a worse Sharpe ratio of -1.05.

Both indices target high-conviction, catalyst-driven themes with similar beta exposure around 0.9, but cybersecurity bets on structural spending trends while biotech plays binary FDA and M&A events.

Cybersecurity fits investors who can stomach extreme volatility for exposure to the zero-trust transformation theme, banking that current weakness reflects temporary headwinds rather than structural problems. Biotech Catalysts suits those seeking more measured volatility around specific, time-bound catalysts, though the poor Sharpe ratio suggests the catalyst timing has been off. Neither index currently rewards the risk taken, but cybersecurity's structural thesis and smaller losses make it the marginally better choice for thematic exposure, assuming investors can handle the wild swings.